Early Signals

Dexcom’s expansion of Stelo continuous glucose monitoring to younger users, the integration of Ultrahuman’s metabolic platform with Abbott Lingo, the European launch of MiniMed Instinct sensors, and evolving coverage discussions highlighted at ADA 2026 collectively indicate that continuous glucose monitoring is evolving into a broader metabolic health platform rather than remaining solely a diabetes management device. Together, these developments point toward CGM becoming foundational infrastructure for personalised nutrition, preventative healthcare and consumer metabolic optimisation.

GRAIL’s $110 million financing from Samsung entities, new Mayo Clinic research using AI to identify pancreatic cancer years before diagnosis, Spotlight Medical’s IVDR CE Mark for its AI breast cancer test, Aidoc’s FDA Breakthrough Device designation for AI-generated radiology reports, and an NHS teledermatology evaluation published in the British Journal of Dermatology collectively indicate that blood-based diagnostics and AI-powered detection platforms are advancing in parallel. Together, these developments suggest the future of early cancer detection may be built on interconnected diagnostic infrastructure spanning molecular testing, medical imaging, pathology and digital triage rather than individual screening technologies.

UpDoc’s FDA-cleared clinical AI platform, Assort Health’s $120 million funding round, a Nature Medicine benchmark analysis of clinical large language models, research highlighting limitations of consumer health chatbots, and emerging California AI governance proposals collectively indicate an early divergence between regulated clinical AI companions and general-purpose consumer chatbots. Together, these developments suggest that future adoption will increasingly depend on clinical validation, governance, regulatory approval and integration into healthcare workflows rather than model capability alone.

Funding from ARPA-H for the OCULAB tear-duct biosensor programme, a University of Sydney sepsis monitoring patch, new implantable aptagel biosensor research published by ACS Sensors, and industry roadmaps outlined by diabetes technology leaders in MedTech Dive’s multi-analyte CGM report collectively indicate that continuous bio-sensing is expanding beyond glucose toward multi-biomarker monitoring. Together, these developments suggest the infrastructure for continuous clinical and preventative health monitoring is beginning to emerge across research, healthcare and commercial device ecosystems.

A partnership between Samsung and Alcedis to develop wearable-based clinical trial endpoints, emerging guidance on digital biomarker validation, a published framework for neurodegenerative digital biomarkers, Medidata’s latest AI clinical trials report, and Epicrispr’s use of digital twins in therapeutic development collectively indicate that wearable data is moving beyond consumer health tracking toward regulated clinical evidence generation. Together, these developments suggest validation standards, interoperability and evidence infrastructure are becoming the critical enablers for scaling digital biomarkers across pharmaceutical research and healthcare.

A partnership between IMU Biosciences and Waters Corporation to advance AI-powered immune mapping, new research into T-cell receptor repertoire profiling, the Capitainer–Triolab distribution partnership, and expanded laboratory integration between Attunio Health, Quest Diagnostics and Getlabs collectively indicate that blood-based AI diagnostics are evolving through connected infrastructure spanning sample collection, immune fingerprinting, laboratory analytics and clinical integration. Together, these developments suggest precision diagnostics are becoming increasingly infrastructure-led, with partnerships across diagnostics, analytics and decentralised testing laying the foundations for broader clinical adoption.